- Case study features BridgeBio’s unique model that uses portfolio theory to enable early-stage research for genetic diseases and conditions that are not typically addressed by the ...

Researchers have controlled the evolution of E. coli bacteria in the lab in order to dramatically increase the amount of plasmid DNA (pDNA) these modified bacteria produce. The advance is ...

--BridgeBio Pharma, Inc., a new type of biopharmaceutical company focused on genetic diseases, today announced that a case study," Applications of Portfolio Theory to Accelerating Biomedical ...

BridgeBio was founded in 2015 on the principles of modern portfolio theory, formulated by financial economist Harry Markowitz in 1952, with a goal of diversifying risk by investing in multiple ...